Lino Patrício, Inês Gonçalves
2622
16. Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparina or unfractionated heparin
in primary percutaneous coronary intervention for ST‑elevation myocardial infarction: the
international randomized open‑label ATOL trial. Lancet. 2011;78:693‑703.
17. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and
conservative strategies in patients with unstable coronary syndromes treated with the
glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001; 344:1879‑1887.
18. ox KA, FPoole‑Wilson P, Clayton TC, et al. 5‑year outcome of an interventional strategy in
non‑ST‑elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised
trial. Lancet 2005; 366:914‑920.
19. Hamm C, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary
syndromes in patients presenting without persistent ST‑segment elevation of the European
Society of Cardiology (ESC). Eur Heart J. 2011;32:2999‑3054.
20. Wallentin L, Becker RC, Budaj A, et al, for the PLATO Investigators.Ticagrelor versus clopidogrel
in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
21. Wiviott SD, Braunwald E, McCabe CH, et al, for the TRITON‑TIMI 38 Investigators. Prasugrel
versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–
2015.
22. Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary
syndromes without revascularization. N Engl J Med. 2012; 367:1297‑309.
23. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use
of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA.
2007;297:591‑602.
24. Giugliano RP,White JA, Bode C, et al on behalf of the EARLY ACS Investigators. Early versus
delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360:2176‑90.
25. Kastrati A, Neumann F‑J, Schulz S, et al on behalf of ISAR‑REACT 4 Trial Investigators.
Abciximab and heparin vs. bivalirudin for non‑ST‑elevation myocardial infarction. N Engl J Med.
2011;365:1980–1989
26. Kastrati A, Neumann F‑J, Mehilli J, et al on behalf of ISAR‑REACT 3Trial Investigators. Bivalirudin
vs. unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008;359:
688–696.
27. Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non‑ST‑segment
elevation acute coronary syndromes: American College of Chest Physicians Evidence‑Based
Clinical Practice Guidelines (8th Edition). Chest. 2008;133:670S–707S.
28. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high‑risk
patients with non‑ST‑segment elevation acute coronary syndromes managed with an intended
early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–
54.
29. Simoons ML, Bobbink IW, Boland J, et al on behalf PENTUA Investigators.A dose‑finding study
of fondaparinux in patients with non‑ST‑segment elevation acute coronary syndromes: the
Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol. 2004;43:2183‑90.
